questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Hémoprotéines
Cytochromes
Cytochrome P-450 enzyme system
Famille-2 de cytochromes P450
Limonène hydroxylases
Limonène hydroxylases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Déficience enzymatique
Tests génétiques
Tests biochimiques
Activité enzymatique
Symptômes
Dysfonction enzymatique
Tests génétiques
Mutations
Symptômes
5
Troubles métaboliques
Réactions allergiques
Éruptions cutanées
Hypersensibilité
Troubles neurologiques
Symptômes
Prévention
5
Alimentation équilibrée
Nutriments
Tests génétiques
Surveillance précoce
Environnement de travail
Exposition
Traitements
5
Traitements symptomatiques
Modifications diététiques
Thérapie génique
Recherche
Thérapies alternatives
Gestion des symptômes
Complications
5
Complications métaboliques
Réactions allergiques
Risques à long terme
Maladies chroniques
Complications neurologiques
Cas rares
Facteurs de risque
5
Antécédents familiaux
Expositions environnementales
Facteurs environnementaux
Produits chimiques
Mode de vie
Complications
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Limonène hydroxylases : Questions médicales les plus fréquentes",
"headline": "Limonène hydroxylases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Limonène hydroxylases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-17",
"dateModified": "2025-04-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Limonène hydroxylases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Famille-2 de cytochromes P450",
"url": "https://questionsmedicales.fr/mesh/D000072467",
"about": {
"@type": "MedicalCondition",
"name": "Famille-2 de cytochromes P450",
"code": {
"@type": "MedicalCode",
"code": "D000072467",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.491"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9",
"url": "https://questionsmedicales.fr/mesh/D065729",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP2C9",
"code": {
"@type": "MedicalCode",
"code": "D065729",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.491.500.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 CYP2C19",
"alternateName": "Cytochrome P-450 CYP2C19",
"url": "https://questionsmedicales.fr/mesh/D065731",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP2C19",
"code": {
"@type": "MedicalCode",
"code": "D065731",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.491.500.700"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Limonène hydroxylases",
"alternateName": "Limonene Hydroxylases",
"code": {
"@type": "MedicalCode",
"code": "D065730",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sasa Liu",
"url": "https://questionsmedicales.fr/author/Sasa%20Liu",
"affiliation": {
"@type": "Organization",
"name": "College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Yuyao Ren",
"url": "https://questionsmedicales.fr/author/Yuyao%20Ren",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian, 116023, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Guojie Jin",
"url": "https://questionsmedicales.fr/author/Guojie%20Jin",
"affiliation": {
"@type": "Organization",
"name": "College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Xiaobing Yang",
"url": "https://questionsmedicales.fr/author/Xiaobing%20Yang",
"affiliation": {
"@type": "Organization",
"name": "College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China. yangxb@nwafu.edu.cn."
}
},
{
"@type": "Person",
"name": "Elham Zarenezhad",
"url": "https://questionsmedicales.fr/author/Elham%20Zarenezhad",
"affiliation": {
"@type": "Organization",
"name": "Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.",
"datePublished": "2023-03-23",
"url": "https://questionsmedicales.fr/article/36952213",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40259-023-00589-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab.",
"datePublished": "2024-09-25",
"url": "https://questionsmedicales.fr/article/39317813",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00384-024-04727-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Infliximab therapy in Behçet's uveitis.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/36150991",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jfo.2022.04.009"
}
},
{
"@type": "ScholarlyArticle",
"name": "Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.",
"datePublished": "2022-08-17",
"url": "https://questionsmedicales.fr/article/35975641",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5009/gnl220005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.",
"datePublished": "2022-06-03",
"url": "https://questionsmedicales.fr/article/35657560",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40261-022-01162-6"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hémoprotéines",
"item": "https://questionsmedicales.fr/mesh/D006420"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cytochromes",
"item": "https://questionsmedicales.fr/mesh/D003580"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytochrome P-450 enzyme system",
"item": "https://questionsmedicales.fr/mesh/D003577"
},
{
"@type": "ListItem",
"position": 7,
"name": "Famille-2 de cytochromes P450",
"item": "https://questionsmedicales.fr/mesh/D000072467"
},
{
"@type": "ListItem",
"position": 8,
"name": "Limonène hydroxylases",
"item": "https://questionsmedicales.fr/mesh/D065730"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Limonène hydroxylases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Limonène hydroxylases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Limonène hydroxylases",
"description": "Comment diagnostiquer une déficience en limonène hydroxylases ?\nQuels tests sont utilisés pour évaluer l'activité des limonène hydroxylases ?\nLes symptômes peuvent-ils indiquer un problème avec les limonène hydroxylases ?\nY a-t-il des biomarqueurs associés aux limonène hydroxylases ?\nComment les tests génétiques aident-ils au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Infliximab#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Limonène hydroxylases",
"description": "Quels symptômes sont liés à une déficience en limonène hydroxylases ?\nLes symptômes varient-ils selon les individus ?\nPeut-on observer des symptômes cutanés ?\nLes symptômes respiratoires sont-ils fréquents ?\nY a-t-il des symptômes neurologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Infliximab#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Limonène hydroxylases",
"description": "Peut-on prévenir les troubles liés aux limonène hydroxylases ?\nY a-t-il des mesures diététiques préventives ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nL'éducation sur les allergies est-elle importante ?\nLes environnements de travail peuvent-ils influencer la santé ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Infliximab#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Limonène hydroxylases",
"description": "Quels traitements sont disponibles pour les troubles liés aux limonène hydroxylases ?\nLa thérapie génique est-elle une option ?\nDes médicaments spécifiques existent-ils ?\nComment la nutrition peut-elle aider ?\nLes traitements alternatifs sont-ils efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Infliximab#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Limonène hydroxylases",
"description": "Quelles complications peuvent survenir avec une déficience en limonène hydroxylases ?\nLes complications sont-elles réversibles ?\nY a-t-il des risques à long terme ?\nLes complications affectent-elles la qualité de vie ?\nDes complications neurologiques sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Infliximab#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Limonène hydroxylases",
"description": "Quels sont les facteurs de risque pour les troubles enzymatiques ?\nL'âge influence-t-il le risque de déficience ?\nLes allergies augmentent-elles le risque ?\nY a-t-il des facteurs environnementaux à considérer ?\nLe mode de vie joue-t-il un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Infliximab#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en limonène hydroxylases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses génétiques peuvent être réalisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des limonène hydroxylases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant l'activité enzymatique dans des échantillons biologiques."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils indiquer un problème avec les limonène hydroxylases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes métaboliques peuvent suggérer une dysfonction enzymatique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés aux limonène hydroxylases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des métabolites spécifiques peuvent servir de biomarqueurs pour l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Comment les tests génétiques aident-ils au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils identifient des mutations dans les gènes codant pour les limonène hydroxylases."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une déficience en limonène hydroxylases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles métaboliques, des réactions allergiques ou des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'expression des symptômes peut varier en fonction de la génétique et de l'environnement."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées peuvent survenir en raison d'une hypersensibilité."
}
},
{
"@type": "Question",
"name": "Les symptômes respiratoires sont-ils fréquents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme l'asthme peuvent être exacerbés par des métabolites du limonène."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques peuvent survenir, mais ils sont moins fréquents."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux limonène hydroxylases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais éviter les allergènes peut aider à réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures diététiques préventives ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en nutriments peut soutenir la santé enzymatique."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier les individus à risque et permettre une surveillance précoce."
}
},
{
"@type": "Question",
"name": "L'éducation sur les allergies est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre les allergies peut aider à éviter les déclencheurs et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les environnements de travail peuvent-ils influencer la santé ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des environnements de travail exposant à des terpènes peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés aux limonène hydroxylases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements symptomatiques et des modifications diététiques peuvent être recommandés."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible pour ces troubles."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques existent-ils ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de médicaments spécifiques pour traiter ces déficiences."
}
},
{
"@type": "Question",
"name": "Comment la nutrition peut-elle aider ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut soutenir la fonction enzymatique."
}
},
{
"@type": "Question",
"name": "Les traitements alternatifs sont-ils efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives peuvent aider à gérer les symptômes, mais peu de preuves."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en limonène hydroxylases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications métaboliques et des réactions allergiques sévères peuvent se produire."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de maladies chroniques peuvent augmenter en raison de l'exposition continue."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent significativement impacter la qualité de vie des individus concernés."
}
},
{
"@type": "Question",
"name": "Des complications neurologiques sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, bien que rares, des complications neurologiques peuvent survenir dans certains cas."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles enzymatiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et des expositions environnementales peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de déficience ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences peuvent se manifester plus tard dans la vie."
}
},
{
"@type": "Question",
"name": "Les allergies augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes allergiques peuvent être plus susceptibles de développer des troubles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à considérer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques et à des terpènes peut être un facteur de risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque de complications liées aux enzymes."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 12/04/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian, 116023, People's Republic of China.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China. yangxb@nwafu.edu.cn.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran. m.osanloo@fums.ac.ir.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Energy Conversion and Storage, Faculty of Chemistry, Gdańsk University of Technology, G. Narutowicza 11/12, PL-80-233 Gdańsk, Poland.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Institute of Fluid-Flow Machinery, Polish Academy of Sciences, Fiszera 14 st., PL-80-231 Gdańsk, Poland.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
School of Food Engineering, Department of Food Science, University of Campinas, Campinas, Brazil.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, USA. vhgrassian@ucsd.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, University of California, Irvine, California 92697, USA. dtobias@uci.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, University of California, Irvine, California 92697, USA. dtobias@uci.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, USA. vhgrassian@ucsd.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA.
Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA.
Center for Synthetic Biology, Northwestern University, Evanston, IL, USA.
Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute Northwestern University, Chicago, IL, USA.
Simpson Querrey Institute Northwestern University, Chicago, IL, USA.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
DECHEMA-Forschungsinstitut, Industrial Biotechnology, Frankfurt am Main, Germany.
Faculty Biological Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
DECHEMA-Forschungsinstitut, Industrial Biotechnology, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
DECHEMA-Forschungsinstitut, Industrial Biotechnology, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
Faculty Biological Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
We aimed to assess whether the introduction of the first infliximab biosimilar was associated with changes in overall infliximab consumption (originator and biosimilars) and price changes to the origi...
An interrupted time series analysis using infliximab sales data from 2010 to 2020 from the IQVIA Multinational Integrated Data Analysis System for eight selected regions: Australia, Canada, Hong Kong,...
Following the introduction of infliximab biosimilars, overall infliximab consumption increased in Australia [immediate change: 0.145 SU/1000 inhabitants (P = 0.014); long-term change: 0.022 SU/1000 in...
Introduction of the first infliximab biosimilar was not consistently associated with increased consumption across regions. Additional policy and healthcare system interventions to support biosimilar i...
Immunogenicity is a major reason for secondary loss of response to infliximab (IFX). Recent work suggested potentially lower immunogenicity of subcutaneous (SC) compared to intravenous (IV) IFX. Howev...
In a retrospective cohort study conducted at two medical centers, patients with clinically (Harvey-Bradshaw Index ≥ 5) and/or biochemically (fecal calprotectin > 250 µg/g) active Crohn's disease (CD) ...
Twenty CD patients were included. The majority of patients (90%) had previous treatment with three or more biologics. Fifteen (75%) and ten (50%) of 20 patients continued IFX SC treatment until months...
Subcutaneous infliximab treatment of Crohn's disease patients with previous immunogenic failure of intravenous infliximab was well tolerated and effective in a cohort of patients with refractory Crohn...
To evaluate the efficacy of infliximab (IFX) therapy in patients with Behçet's uveitis (BU) refractory to conventional immunomodulatory treatment (IMT)....
This study, trial registration number TCTR20200806007, included cases of BU with a minimum of 18 months follow-up on IFX treatment. Demographic characteristics, ophthalmological examination findings, ...
Sixty-two eyes of 35 patients on IFX therapy were included in the study. The mean follow-up was 49.5±25.9months. The mean frequency of recurrences during the IMT was 1.47±0.78 (attacks/year), decreasi...
IFX is a safe and effective treatment in cases of BU refractory to conventional IMT....
The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn's disease in CT-P13 3.4 study (NCT02096861). We performed a multivariate logistic analysis to demonstrate t...
Early serum infliximab trough levels and anti-drug antibody (ADA) levels were compared between CT-P13 (n=100) and originator infliximab (n=98) groups. Receiver operating characteristic (ROC) analysis ...
The median infliximab trough levels were not different between CT-P13 and originator infliximab groups at week 6, week 14, and in median ADA levels at week 14, respectively. ROC analysis found an infl...
A threshold in serum infliximab trough level at week 6 and week 14 was highly predictive for long-term clinical outcomes. There were no statistical differences in serum infliximab trough levels and AD...
Subcutaneous infliximab recently received approval for the treatment of various immune-mediated inflammatory diseases in Europe, following pivotal clinical trials in patients with rheumatoid arthritis...
Vascular involvement is an important cause of morbidity and mortality in patients with Behçet's syndrome (BS). We aimed to survey the efficacy and safety of infliximab (IFX) in BS patients with vascul...
Charts of all BS patients who used IFX for vascular involvement between 2004 and 2022 were reviewed. Primary endpoint was remission at Month 6, defined as lack of new clinical symptoms and findings as...
Among the 127 patients (102 men, mean age at IFX initiation: 35.8 ± 9.0 years) treated with IFX, 110 (87%) had received IFX for remission induction and 87 of these (79%) were already on immunosuppress...
Infliximab seems to be effective in majority of BS patients with vascular involvement, even in those who are refractory to immunosuppressives and glucocorticoids....
As the third year of the SARS-CoV-2 pandemic approaches, COVID-19 continues to cause substantial morbidity and mortality due to waning vaccine efficacy and the emergence of new, highly contagious subv...
Hospitalized patients who develop hypoxia due to SARS-CoV-2 infection are typically treated with an antiviral agent, remdesivir, as well as an immunomodulator, dexamethasone, but mortality rates for s...
On 2 June 2022, the United States National Institutes of Health reported results from a large, randomized placebo-controlled clinical trial known as ACTIV-1. The study found a mortality benefit and su...
Clinical remission has been achieved with infliximab in patients with refractory ulcerative colitis (UC). However, there is conflicting data regarding its effectiveness as rescue therapy in adult acut...
A single-institution, retrospective review was conducted of pediatric patients with UC or indeterminate colitis who received inpatient rescue infliximab therapy from 1/2000 to 1/2019. Rescue inflixima...
Thirty patients met inclusion criteria. The median age at administration of rescue infliximab treatment was 14 years [IQR 13,17]. Rescue therapy with infliximab was successful in 33% (n = 10), while 6...
In severe acute ulcerative or indeterminate colitis cases where infliximab has not been previously used, rescue infliximab can be used to avoid colectomy but has a high failure rate....
IV....
Retrospective study....
Patients with various cancers benefit from immune checkpoint inhibitors. However, immune checkpoint inhibitor-induced adverse events have also been reported, such as colitis. Prednisolone is the first...
Cyclophosphamide and infliximab are recommended as induction therapies for severe Behçet's syndrome. Whether infliximab is safer and more effective than cyclophosphamide in treating severe Behçet's sy...
In this phase 2, Bayesian, multicenter randomized controlled trial, we assigned patients fulfilling the International Study Group's criteria for Behçet's syndrome who had major vascular or central ner...
Between May 2018 and April 2021, 52 patients with severe Behçet's syndrome (n=37 [71%] with vascular Behçet's syndrome and n=15 [29%] with neuro-Behçet's syndrome) were randomly assigned to receive ei...
Among patients with severe Behçet's syndrome, induction therapy with infliximab had a superior complete response rate at 22 weeks and fewer adverse events than induction with cyclophosphamide. (Funded...